GlaxoSmithKline
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Efficacy Study of HPV-16/18 Vaccine (GSK 580299) to Prevent HPV-16 and/or -18 Cervical Infection in Young Healthy Women
- Conditions
- Infections, Papillomavirus
- Interventions
- Biological: CervarixBiological: placebo
- First Posted Date
- 2008-06-04
- Last Posted Date
- 2016-09-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1113
- Registration Number
- NCT00689741
Mild Alzheimer''s Disease to Assess the of Extended Release Formulation of Rosiglitazone (RSG XR)
- First Posted Date
- 2008-06-02
- Last Posted Date
- 2016-11-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 14
- Registration Number
- NCT00688207
- Locations
- π©πͺ
GSK Investigational Site, Berlin, Germany
Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma
- First Posted Date
- 2008-06-02
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 206
- Registration Number
- NCT00687622
- Locations
- πΊπΈ
GSK Investigational Site, Norfolk, Virginia, United States
Study In Healthy Subjects To Evaluate The Photo-Irritant Potential Of Eltrombopag
- Conditions
- Purpura, Thrombocytopaenic, Idiopathic
- Interventions
- First Posted Date
- 2008-06-02
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 36
- Registration Number
- NCT00688272
- Locations
- π¬π§
GSK Investigational Site, Dundee, United Kingdom
Study to Evaluate SC Route of Administration of Ofatumumab in RA Patients
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2017-06-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 35
- Registration Number
- NCT00686868
- Locations
- πͺπΈ
GSK Investigational Site, Madrid, Spain
Evaluation of Immune Memory to Twinrix or Comparator by Challenge Dose Administration 4 Years After Primary Vaccination
- Conditions
- Hepatitis BHepatitis A
- Interventions
- Biological: Engerix-BBiological: TwinrixBiological: HBVAXPROBiological: HavrixBiological: Vaqta
- First Posted Date
- 2008-05-28
- Last Posted Date
- 2018-08-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 506
- Registration Number
- NCT00684671
- Locations
- π¨πΏ
GSK Investigational Site, Hradec Kralove, Czechia
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
- Conditions
- Lung Cancer, Non-Small Cell
- Interventions
- Procedure: Collection of tumor and blood samples
- First Posted Date
- 2008-05-28
- Last Posted Date
- 2019-06-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 88
- Registration Number
- NCT00685750
- Locations
- πΈπͺ
GSK Investigational Site, Stockholm, Sweden
Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL)
- Conditions
- Skin Infections, Bacterial
- Interventions
- Drug: Placebo ointment
- First Posted Date
- 2008-05-26
- Last Posted Date
- 2016-11-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 508
- Registration Number
- NCT00684177
- Locations
- πΏπ¦
GSK Investigational Site, Worcester, South Africa
A Phase I Study Of Oral Topotecan And Lapatinib In Subjects With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2008-05-22
- Last Posted Date
- 2015-04-17
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT00682279
- Locations
- πΊπΈ
GSK Investigational Site, Philadelphia, Pennsylvania, United States
A Clinical Study With Fluticasone Furoate Nasal Spray And Vehicle Placebo For The Treatment Of Perennial (Year-round) Allergic Rhinitis
- Conditions
- Rhinitis, Allergic, Perennial
- Interventions
- Drug: vehicle placebo nasal spray
- First Posted Date
- 2008-05-22
- Last Posted Date
- 2017-01-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 550
- Registration Number
- NCT00682643
- Locations
- πΊπΈ
GSK Investigational Site, Greenfield, Wisconsin, United States